Microbot Medical reports over 100% revenue growth in Q2 2026

Go back to Microbot Medical reports over 100% revenue growth in Q2 2026

Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026

July 7, 2026 8:30 AM EDT

The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April

Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S. sales territories from 8 to 12 and enter international markets by the end of 2026

HINGHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is reporting greater than 100% growth in revenue and new... More